Cardiosonic develops pioneering solutions for transluminal high-intensity ultrasound ablation. The company’s flagship application, the TIVUS high-intensity, directional ultrasound catheter system enables remote, localized, controlled and repeatable thermal modulation of the renal vessel wall tissue, to perform safe therapeutic renal sympathetic denervation by ultrasound ablation, for resistant hypertension. Based on proven connection between hyper-activation of the sympathetic nervous system and the pathophysiology of hypertension, therapeutic renal sympathetic denervation has been shown to induce a reduction in blood pressure. With the potential to introduce a new standard of care, the TIVUS system technology addresses one of medicine’s most pressing challenges. In preclinical trials, the company’s flagship TIVUS system has shown excellent results.

Backed by a strong IP position and a multidisciplinary team of experienced experts in ultrasound technologies, catheter design, clinical trials and regulatory issues, the company is uniquely poised to lead the market toward expanded use of endovascular ultrasound solutions for a myriad of other applications, such as reducing post-PTA restenosis, atrial fibrillation pathway ablation, atherosclerotic plaque passivation, benign prostatic hypertrophy, CHF, type 2 diabetes, sleep apnea and renal failure — offering the hope of a safe, cath lab procedure to growing numbers of high-risk patients.
Cardiosonic is a privately owned company with headquarters in Israel. For more information, please contact: